Paysign (PAYS) Q4 2025 earnings review
Explosive Pharma Growth Triggers Massive 2026 Profit Upgrade
Paysign delivered a transformative 2025, culminating in Q4 revenue growth accelerating to 45.8% YoY. The star of the show is the Patient Affordability (Pharma) segment, which grew 122.4% in the quarter and drove substantial operating leverage. While Q4 net income was flat YoY due to a 45.4% effective tax rate, Adjusted EBITDA surged nearly 90%. Looking ahead, management dropped highly bullish 2026 guidance, projecting Net Income to nearly double as the higher-margin pharma business rapidly scales and the legacy plasma segment returns to growth.
🐂 Bull Case
The mix shift toward the Patient Affordability segment is structurally elevating the company's margin profile. 2026 guidance targets $30.0M to $33.0M in Adjusted EBITDA, a massive 58% growth at the midpoint, vastly outpacing the 30-35% expected revenue growth.
Despite severe industry headwinds earlier in the year, the strategic addition of 115 net plasma centers in 2025 successfully offset lower individual center volumes, reversing the segment back to 16.7% YoY revenue growth in Q4.
🐻 Bear Case
Average revenue per plasma center per month declined to $7,067 in Q4 from $7,510 a year ago, illustrating that volume growth is currently dependent entirely on acquiring new centers rather than organic donor expansion.
Despite the favorable mix shift towards pharma, Q4 gross margin actually decelerated to 57.7% (down from 58.9% in Q4 2024), driven by wage inflation and startup costs associated with a new customer service contact center.
⚖️ Verdict: 🟢
Bullish. The strategic pivot from a legacy plasma payments provider to a diversified life sciences fintech platform is working beautifully. The explosive growth of the Pharma segment is absorbing the lumpiness of the Plasma segment, and 2026 guidance indicates the company is entering a period of significant free cash flow generation.
Key Themes
Pharma Segment Scales Aggressively
Patient Affordability continues to be the primary growth engine, exiting the year with 131 active programs (up 55 YoY). Q4 pharma revenue surged 122.4% to $9.60 million. Claim volume increased over 79% for the full year, cementing the segment's role as a high-margin anchor for the consolidated business.
Plasma Segment Overcomes Industry Headwinds
Reversing its decline from early 2025, the legacy Plasma industry segment grew 16.7% YoY in Q4 to $12.60 million. This stabilization was achieved through aggressive market share expansion rather than organic growth, as the company exited the year with 595 centers, a net increase of 115 from the prior year.
Cost Base Inflation Pressuring Short-Term Gross Margins
While full-year gross profit margin expanded, Q4 isolated gross margin decelerated to 57.7% from 58.9% YoY. Management explicitly cited increased call center support expense, wage inflation pressures, and a tight labor market as factors driving a 50.4% YoY jump in Q4 Cost of Revenues.
Regulatory Delays for New SaaS Platform
The Blood Establishment Computer System (BECS), acquired via Gamma Innovation, remains under U.S. FDA review. Previous quarter call transcripts indicated the government shutdown pushed this timeline out, leaving the monetization of this strategic SaaS pivot in a holding pattern.
Other KPIs
The Q4 tax rate skyrocketed to 45.4% compared to a benefit of -11.1% in Q4 2024. This massive discrepancy artificially depressed Net Income, making the $1.36M bottom-line result look flat YoY despite an 89.6% surge in Adjusted EBITDA. Full-year tax rate normalized to 24.7%.
Restricted cash balances climbed 29.0% YoY. These funds represent customer card funding and pharmaceutical claim reimbursements. While they carry corresponding liabilities, the sheer size of the float allows Paysign to generate substantial interest income ($2.67M in FY25), shielding the company from operational cash crunches.
Decelerating. Down from $7,510 in Q4 2024, continuing a full-year trend of weaker unit economics caused by elevated plasma inventory levels and the dilutive effect of onboarding new, immature donation centers.
Guidance
Accelerating structurally. The midpoint of $108.5M implies a 32.3% YoY growth rate. Management explicitly expects Plasma and Pharma to contribute equally, suggesting Pharma will cross the $50M threshold, effectively closing the historical gap with the legacy Plasma business.
Accelerating significantly. At the midpoint ($14.5M), this represents an astonishing 92% YoY growth compared to the $7.55M printed in FY25, validating the margin expansion thesis as high-margin Pharma revenues scale past fixed corporate overhead.
Accelerating. Implies a blockbuster 45.2% to 47.8% YoY growth rate for the immediate upcoming quarter. Management notes Q1 is highly seasonal for the Pharma segment as patient affordability claims ramp up at the start of new deductible cycles.
Stable. While Opex is forecasted to rise 20%, it severely lags the 30-35% expected revenue growth, generating massive operating leverage. Depreciation and amortization will sit between $9.5M and $10.0M due to ongoing technology investments.
Key Questions
Pharma Margin Profile at Scale
With Pharma revenues projected to match Plasma revenues in 2026, will the new customer service contact center be sufficient to handle this volume, or should we model further step-function increases in cost of revenues?
Plasma Unit Economics Turnaround
Average revenue per center remains depressed at ~$7,067. What specific market signals or internal maturity timelines give you confidence this metric will stabilize or inflect positively in 2026?
BECS Commercialization Strategy
Assuming FDA clearance is achieved for the Blood Establishment Computer System, what is the anticipated timeline for revenue contribution, and how will the pricing model differ from your traditional transaction-based fees?